Company Analysis
Sign in

OnKure Therapeutics, Inc. (OKUR)

Nasdaq: OKUR · Pharmaceutical Preparations · Boulder, CO · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.9
◀ Past 6.8● Present 4.4▶ Future 6.5
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to OnKure Therapeutics, Inc.’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 2 in 2023
Applications published
18
1 of them in 2025
Names they are printed under
3
a subsidiary, a former name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals7
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
OnKure, Inc. a subsidiary
US, as the owner printed on each patent
7 granted
9 published
Reneo Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
0 granted
9 published
RENEO PHARMACEUTICALS, INC. a former name
US, as the owner printed on each patent
3 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 18, 202512,252,511Process for the preparation of cyclic depsipeptidesPharmaceuticalsOnKure, Inc.
Mar 19, 202411,931,365Use of PPAR-delta agonists in the treatment of diseasePharmaceuticalsRENEO PHARMACEUTICALS, INC.
Aug 29, 202311,739,123Process for the preparation of cyclic depsipeptidesPharmaceuticalsOnKure, Inc.
Aug 1, 202311,713,301Crystalline PPARδ agonistPharmaceuticalsRENEO PHARMACEUTICALS, INC.
May 24, 202211,339,150Benzimidazole compounds as HDAC6 inhibitorsOrganic fine chemistryOnKure, Inc.
Mar 8, 202211,267,795Crystalline PPAR-delta agonistPharmaceuticalsRENEO PHARMACEUTICALS, INC.
Dec 21, 202111,203,602Thioester prodrugs of macrocycles as inhibitors of histone deacetylasesPharmaceuticalsOnKure, Inc.
Jul 6, 202111,053,284Process for the preparation of cyclic depsipeptidesPharmaceuticalsOnKure, Inc.
Jun 23, 202010,689,419Process for the preparation of cyclic depsipeptidesPharmaceuticalsOnKure, Inc.
Oct 16, 201810,100,089Process for the preparation of cyclic depsipeptidesPharmaceuticalsOnKure, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 15, 20252025/0152560HDAC INHIBITOR OKI-179 IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF CANCERPharmaceuticalsOnKure, Inc.
Apr 11, 20242024/0116989PROCESS FOR THE PREPARATION OF CYCLIC DEPSIPEPTIDESPharmaceuticalsOnKure, Inc. · patent 12,252,511 granted from it
Jan 18, 20242024/0016809USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASEPharmaceuticalsReneo Pharmaceuticals, Inc.
Jan 4, 20242024/0002356CRYSTALLINE PPAR-DELTA AGONISTPharmaceuticalsReneo Pharmaceuticals, Inc.
Dec 28, 20232023/0416210METHODS OF MAKING A PPAR-DELTA AGONISTOrganic fine chemistryReneo Pharmaceuticals, Inc.
Jul 27, 20232023/0233570USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASEPharmaceuticalsReneo Pharmaceuticals, Inc. · patent 11,931,365 granted from it
Nov 24, 20222022/0370467USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASEPharmaceuticalsReneo Pharmaceuticals, Inc.
May 5, 20222022/0135532CRYSTALLINE PPAR-DELTA AGONISTPharmaceuticalsReneo Pharmaceuticals, Inc. · patent 11,713,301 granted from it
Apr 21, 20222022/0117972USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHYPharmaceuticalsReneo Pharmaceuticals, Inc.
Feb 10, 20222022/0041584BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORSOrganic fine chemistryOnKure, Inc. · patent 11,339,150 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton OKUR · research, not advice